“…Because small changes can have a huge impact on bioactive profile, this approach offers unique opportunities for the generation of new drug-like analogs of lead structures without extra synthetic steps or resorting to de novo synthesis [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. While various reviews on C–H functionalization of heteroarenes have been already published [ 18 , 19 , 20 , 21 , 22 ], they are mainly focused on transition metal catalysis. In the quest for mild and sustainable late-stage functionalization, transition-metal-free diversification appears as a rewarding tool to build new functionalized heteroarene derivatives onto their established bioactive framework [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ].…”